In parallel with the evolution of cancer therapies over time, the field of molecular diagnostics continues to mature, bringing innovative solutions to precision medicine. The value of using molecular residual disease (MRD) to monitor a patient’s journey post-diagnosis has demonstrated value in oncology, but is this tool sufficient for clinicians to make informed treatment decisions throughout the patient’s journey? By combining multiple analyses in a platform-based approach, Personalis is developing a holistic solution to managing a patient’s care including therapy selection, treatment, and recurrence monitoring, all from a single specimen collected at clinical diagnosis.
Stephane Mouradian, Ph.D., leads the Business Development & Marketing team at Personalis. Previously, Stephane was at Illumina where he led Illumina’s companion diagnostic partnerships with pharmaceutical companies in oncology, the international expansion of NIPT (Non Invasive Prenatal Testing) and Illumina’s venture investments in start-ups such as Twist Biosciences (synthetic biology) and Boreal Genomics (liquid biopsy), for which he served as Illumina-appointed board observer. Prior to Illumina, Stephane was at Caliper Life Sciences for 15 years. He developed and launched several microfluidic DNA and protein testing products that became standards in genomic laboratories today, and he led corporate development for Caliper. Stephane holds a Ph.D. in Analytical Chemistry from the University of Wisconsin, Madison and a Master’s degree in Chemical Engineering from Strasbourg University, France.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.